Trial Profile
Global phase III trial of a pegfilgrastim (PEG-G-CSF) biosimilar.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 May 2015
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Autoimmune disorders; Cancer
- Focus Therapeutic Use
- 12 May 2015 New trial record